NO20074324L - Substituerte arylamin sammensetniger og deres andvendelse som 5-HT6 modulatorer - Google Patents
Substituerte arylamin sammensetniger og deres andvendelse som 5-HT6 modulatorerInfo
- Publication number
- NO20074324L NO20074324L NO20074324A NO20074324A NO20074324L NO 20074324 L NO20074324 L NO 20074324L NO 20074324 A NO20074324 A NO 20074324A NO 20074324 A NO20074324 A NO 20074324A NO 20074324 L NO20074324 L NO 20074324L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- aryl
- substituted
- heteroaryl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Oppfinnelsen angår nye 5-HT6 reseptor antagonister. Nye arylamin forbindelser med formel: og farmasøytisk akseptable salter og/eller estere derav, der - n er 0, 1, 2, 3, eller 4; - A, når til stede er en lavere alkyl gruppe; - R] er hydrogen eller substituert eller usubstituerte alkyl eller aryl; - R_2 er hydrogen; halo; nitro; cyano, lavere alkoksy; karboksylat salt syre eller alkyl ester derav; et sulfon; haloalkyl eller haloalkoksy; acetaldehyd; karboksamid; karbomyl; alkoksyaminkarbonyl; eller substituert arylalkylamin: - R3 og R4 er uavhengig hydrogen, substituert eller usubstituert alkyl, aryl, alkylaryl, heteroaryl eller alkylheteroaryl, eller tatt sammen danner R;, og R4 en substituert eller usubstituert aryl, alkylaryl, heteroaryl eller alkylheteroaryl gruppe; - B, når til stede, er lavere alkyl; og - X og Y er uavhengig C eller N; og anvendelse av disse forbindelsene og deres farmasøytiske sammensetninger, for eksempel i behandling, modulering og/eller forebygging av fysiologiske tilstander forbundet med serotonin virkning, slik som i behandling av fedme, og fedme-relaterte forstyrrelser for eksempel kardiovaskulær sykdom, fordøyelsessykdom, respiratorisk sykdom, cancer og type II diabetes; og fysiologiske forstyrrelser slik som schizofreni blir beskrevet.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64695705P | 2005-01-25 | 2005-01-25 | |
US70185305P | 2005-07-22 | 2005-07-22 | |
PCT/US2006/002718 WO2006081332A1 (en) | 2005-01-25 | 2006-01-25 | Substituted arylamine compounds and their use as 5-ht6 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20074324L true NO20074324L (no) | 2007-10-25 |
Family
ID=36406535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20074324A NO20074324L (no) | 2005-01-25 | 2007-08-24 | Substituerte arylamin sammensetniger og deres andvendelse som 5-HT6 modulatorer |
Country Status (14)
Country | Link |
---|---|
US (2) | US7968538B2 (no) |
EP (1) | EP1856075A1 (no) |
JP (2) | JP5186219B2 (no) |
KR (1) | KR20070097590A (no) |
AU (1) | AU2006209216A1 (no) |
BR (1) | BRPI0606110A2 (no) |
CA (1) | CA2595607C (no) |
IL (1) | IL184705A0 (no) |
MA (1) | MA29429B1 (no) |
MX (1) | MX2007008279A (no) |
NO (1) | NO20074324L (no) |
NZ (1) | NZ556761A (no) |
RU (1) | RU2440996C2 (no) |
WO (1) | WO2006081332A1 (no) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7482337B2 (en) * | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7153858B2 (en) * | 2003-01-31 | 2006-12-26 | Epix Delaware, Inc. | Arylpiperazinyl compounds |
US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
US20050222175A1 (en) * | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
DE102004009039A1 (de) * | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel |
US7488736B2 (en) * | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
DE102004030502A1 (de) * | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
US7576211B2 (en) * | 2004-09-30 | 2009-08-18 | Epix Delaware, Inc. | Synthesis of thienopyridinone compounds and related intermediates |
US7407966B2 (en) * | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
US7598265B2 (en) * | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
EP1676842A1 (en) * | 2004-12-30 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments |
KR20070097590A (ko) | 2005-01-25 | 2007-10-04 | 에픽스 델라웨어, 인코포레이티드 | 치환된 아릴아민 화합물 및 5―ht6 조절제로서의 이의용도 |
AR061637A1 (es) * | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
MX2009006334A (es) | 2006-12-19 | 2009-06-23 | Hoffmann La Roche | Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona. |
NZ579766A (en) | 2007-03-23 | 2012-03-30 | Abbott Gmbh & Co Kg | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
ES2353297B1 (es) * | 2008-03-18 | 2011-09-26 | Laboratorios Del Dr. Esteve, S. A. | Procedimiento para la preparación de n-(1-feniletil)anilinas, sales, y solvatos de las mismas útiles como antagonistas de 5-ht6 de serotonina. |
EP2103596A1 (en) | 2008-03-18 | 2009-09-23 | Laboratorios Del. Dr. Esteve, S.A. | Process for the preparation of N-(phenylethyl) anilines salts and solvates thereof useful as serotonin 5-HT6 antagonists |
US8114894B2 (en) * | 2008-12-03 | 2012-02-14 | Nanotherapeutics, Inc. | Bicyclic compounds and methods of making and using same |
RU2012139491A (ru) | 2010-02-11 | 2014-03-20 | Вандербилт Юниверсити | Бензизоксазолы и азабензизоксазолы как аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций |
TWI458145B (zh) | 2011-12-20 | 2014-10-21 | Ind Tech Res Inst | 超導材料的接合方法 |
MX2016007219A (es) | 2013-12-03 | 2016-09-16 | Intra-Cellular Therapies Inc | Metodos novedosos. |
JP7013454B2 (ja) | 2016-10-12 | 2022-02-15 | イントラ-セルラー・セラピーズ・インコーポレイテッド | アモルファス固体分散体 |
EP3548034A4 (en) * | 2016-12-05 | 2020-07-08 | Microbiotix, Inc. | BROADBAND SPECTRUM INHIBITORS OF FILOVIRUS |
MX2021013640A (es) | 2017-03-24 | 2022-08-31 | Intra Cellular Therapies Inc | Composiciones novedosas y metodos. |
CN111093662B (zh) | 2017-06-20 | 2023-10-03 | 安布里亚制药公司 | 用于提高心脏代谢效率的组合物和方法 |
KR101992621B1 (ko) | 2017-12-07 | 2019-09-27 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
CN112584837A (zh) | 2018-08-31 | 2021-03-30 | 细胞内治疗公司 | 新方法 |
CA3108558A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
CN112574201B (zh) * | 2019-09-29 | 2024-04-19 | 四川科伦博泰生物医药股份有限公司 | 芳基胺类化合物、包含其的药物组合物及其制备方法和用途 |
US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US20240092756A1 (en) | 2020-11-20 | 2024-03-21 | 2692372 Ontario, Inc. | Methods and composition for kras modifications |
US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1211359B (de) * | 1955-11-29 | 1966-02-24 | Oreal | Oxydationsmittelfreies Kaltfaerbemittel fuer menschliches Haar |
JPH0413669A (ja) | 1990-04-27 | 1992-01-17 | Mitsui Toatsu Chem Inc | 新規ピリミジンジオン誘導体及び該化合物を含有する抗不整脈剤 |
DE4238994A1 (de) | 1992-11-19 | 1994-05-26 | Basf Ag | Aniline als Markierungsmittel für Mineralöle |
JPH07300474A (ja) * | 1994-05-02 | 1995-11-14 | Asahi Chem Ind Co Ltd | テトラハイドロキノキサリン誘導体およびその用途 |
FR2722788B1 (fr) * | 1994-07-20 | 1996-10-04 | Pf Medicament | Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant |
EP0783502A1 (en) | 1995-08-02 | 1997-07-16 | J. URIACH & CIA. S.A. | New carboxamides with antifungal activity |
FR2740134B1 (fr) * | 1995-10-18 | 1998-01-09 | Pf Medicament | Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant |
US6391871B1 (en) | 1996-09-20 | 2002-05-21 | John W. Olney | Preventing neuronal degeneration in Alzheimer's disease |
US20010051719A1 (en) | 1996-12-19 | 2001-12-13 | Smithkline Beecham P.L.C. | Novel compounds |
ATE241358T1 (de) | 1997-03-03 | 2003-06-15 | Eisai Co Ltd | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen |
FR2761064B1 (fr) * | 1997-03-20 | 1999-06-04 | Pf Medicament | Piperazines derivees d'amines cycliques, leur preparation et leur application comme medicaments |
HU226859B1 (en) * | 1997-10-27 | 2009-12-28 | Neurosearch As | Phenyl- or heteroaryl-homopiperazines, their use and medicaments containing them |
EP1054004B1 (en) * | 1997-12-15 | 2008-07-16 | Astellas Pharma Inc. | Novel pyrimidine-5-carboxamide derivatives |
IT1304904B1 (it) | 1998-09-11 | 2001-04-05 | Eisai Co Ltd | Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche |
JP2002534411A (ja) | 1999-01-07 | 2002-10-15 | ワイス | 鬱病の処置のためのアリールピペラジニル−シクロヘキシルインドール誘導体 |
US6972287B1 (en) | 1999-06-10 | 2005-12-06 | Pfizer Inc. | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
WO2000078728A1 (en) * | 1999-06-22 | 2000-12-28 | Neurosearch A/S | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
US6610713B2 (en) | 2000-05-23 | 2003-08-26 | North Shore - Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
PE20020063A1 (es) * | 2000-06-20 | 2002-01-30 | Upjohn Co | Bis-arilsulfonas como ligandos del receptor de 5-ht |
US20040122090A1 (en) | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
AU2002245692A1 (en) | 2001-03-15 | 2002-10-03 | David Pharmaceuticals | Methods for restoring cognitive function following systemic stress |
EP1389194A2 (en) * | 2001-04-27 | 2004-02-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
CN1329382C (zh) | 2001-05-11 | 2007-08-01 | 比奥维特罗姆股份公司 | 治疗肥胖、ⅱ型糖尿病和cns-疾病的芳基磺酰胺化合物 |
US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
EP1429765A2 (en) * | 2001-09-14 | 2004-06-23 | Methylgene, Inc. | Inhibitors of histone deacetylase |
AU2003220184A1 (en) * | 2002-03-20 | 2003-10-08 | Schering Aktiengesellschaft | Substituted piperazine antithrombotic pai-1 inhibitors |
WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
TW200403243A (en) | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
ES2445208T3 (es) | 2002-07-29 | 2014-02-28 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias |
WO2004078732A1 (fr) * | 2003-01-28 | 2004-09-16 | Aventis Pharma S.A. | Produits n-aryl-heteroaromatiques, compositions les contenant et utilisation |
US7153858B2 (en) | 2003-01-31 | 2006-12-26 | Epix Delaware, Inc. | Arylpiperazinyl compounds |
AR043467A1 (es) | 2003-03-05 | 2005-07-27 | Osmotica Argentina S A | Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson |
GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
US7612078B2 (en) | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
US7030240B2 (en) | 2003-03-31 | 2006-04-18 | Predix Pharmaceuticals Holdings, Inc. | Piperidinylamino-thieno[2,3-d] pyrimidine compounds |
US20060148721A1 (en) | 2003-06-06 | 2006-07-06 | Erondu Ngozi E | Combination therapy for the treatment of dyslipidemia |
WO2005016025A2 (en) | 2003-07-24 | 2005-02-24 | Cargill, Incorporated | A food composition contain lecithin |
ES2222827B1 (es) | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
GB0321710D0 (en) * | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
US20050143350A1 (en) | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
US20050209218A1 (en) | 2004-02-13 | 2005-09-22 | Meyerson Laurence R | Methods and compositions for the treatment of psychiatric conditions |
US7488736B2 (en) | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
GB0411791D0 (en) * | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
US7407966B2 (en) | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
US7598265B2 (en) | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
US7576211B2 (en) | 2004-09-30 | 2009-08-18 | Epix Delaware, Inc. | Synthesis of thienopyridinone compounds and related intermediates |
EP1799264A2 (en) | 2004-10-08 | 2007-06-27 | Neuromolecular Pharmaceuticals Inc | Methods and compositions for treating migraine pain |
EP1828185B1 (en) * | 2004-12-21 | 2009-05-06 | SmithKline Beecham Corporation | 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors |
KR101328273B1 (ko) | 2004-12-28 | 2013-11-14 | 키넥스 파마슈티컬즈, 엘엘씨 | 세포 증식 질환의 치료를 위한 조성물 및 방법 |
EP1676842A1 (en) * | 2004-12-30 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments |
EP1695971A1 (en) * | 2004-12-30 | 2006-08-30 | Laboratorios Del Dr. Esteve, S.A. | Substituted phenyl-piperazine compounds, their preparation and use in medicaments |
KR20070097590A (ko) | 2005-01-25 | 2007-10-04 | 에픽스 델라웨어, 인코포레이티드 | 치환된 아릴아민 화합물 및 5―ht6 조절제로서의 이의용도 |
JP5731094B2 (ja) | 2005-02-11 | 2015-06-10 | スティーブン・ウィルスStephen WILLS | アセチルコリンエステラーゼ阻害剤による微小血管系疾患の治療 |
US20060194723A1 (en) | 2005-02-28 | 2006-08-31 | Rabinoff Michael D | Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement |
PT2982372T (pt) | 2005-04-05 | 2020-10-09 | Univ Yale | Agentes moduladores do glutamato no tratamento de distúrbios mentais |
US20060270650A1 (en) | 2005-05-26 | 2006-11-30 | Macneil Tanya | Combination therapy for the treatment of obesity |
AU2006317689B2 (en) | 2005-11-23 | 2013-07-25 | Epix Delaware, Inc. | S1P receptor modulating compounds and use thereof |
US7919519B2 (en) | 2005-11-23 | 2011-04-05 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
CA2646469A1 (en) | 2006-03-21 | 2007-09-27 | Epix Delaware, Inc. | S1p receptor modulating compounds |
-
2006
- 2006-01-25 KR KR1020077019390A patent/KR20070097590A/ko not_active Application Discontinuation
- 2006-01-25 AU AU2006209216A patent/AU2006209216A1/en not_active Abandoned
- 2006-01-25 MX MX2007008279A patent/MX2007008279A/es active IP Right Grant
- 2006-01-25 US US11/340,079 patent/US7968538B2/en not_active Expired - Fee Related
- 2006-01-25 EP EP06719542A patent/EP1856075A1/en not_active Withdrawn
- 2006-01-25 RU RU2007132161/04A patent/RU2440996C2/ru not_active IP Right Cessation
- 2006-01-25 WO PCT/US2006/002718 patent/WO2006081332A1/en active Application Filing
- 2006-01-25 BR BRPI0606110-9A patent/BRPI0606110A2/pt not_active IP Right Cessation
- 2006-01-25 CA CA2595607A patent/CA2595607C/en not_active Expired - Fee Related
- 2006-01-25 JP JP2007552407A patent/JP5186219B2/ja not_active Expired - Fee Related
- 2006-01-25 NZ NZ556761A patent/NZ556761A/en not_active IP Right Cessation
-
2007
- 2007-07-18 IL IL184705A patent/IL184705A0/en unknown
- 2007-08-07 MA MA30129A patent/MA29429B1/fr unknown
- 2007-08-24 NO NO20074324A patent/NO20074324L/no not_active Application Discontinuation
-
2011
- 2011-05-10 US US13/104,450 patent/US8604021B2/en not_active Expired - Fee Related
-
2012
- 2012-03-16 JP JP2012060984A patent/JP2012111784A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
BRPI0606110A2 (pt) | 2009-06-02 |
KR20070097590A (ko) | 2007-10-04 |
US20060205737A1 (en) | 2006-09-14 |
AU2006209216A1 (en) | 2006-08-03 |
US7968538B2 (en) | 2011-06-28 |
RU2007132161A (ru) | 2009-03-10 |
EP1856075A1 (en) | 2007-11-21 |
MX2007008279A (es) | 2008-02-15 |
US20120115850A1 (en) | 2012-05-10 |
WO2006081332A1 (en) | 2006-08-03 |
MA29429B1 (fr) | 2008-05-02 |
CA2595607A1 (en) | 2006-08-03 |
IL184705A0 (en) | 2007-12-03 |
JP2012111784A (ja) | 2012-06-14 |
CA2595607C (en) | 2014-07-15 |
JP2008528517A (ja) | 2008-07-31 |
NZ556761A (en) | 2011-04-29 |
JP5186219B2 (ja) | 2013-04-17 |
RU2440996C2 (ru) | 2012-01-27 |
US8604021B2 (en) | 2013-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20074324L (no) | Substituerte arylamin sammensetniger og deres andvendelse som 5-HT6 modulatorer | |
CA2994688C (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
ES2436103T3 (es) | Derivados de isoxazol y uso de los mismos | |
AU2015230127B2 (en) | Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | |
WO2012068406A2 (en) | Use of hematopoietic growth factor mimetics | |
WO2005012221A1 (ja) | ジフェニルエーテル化合物、その製造方法および用途 | |
KR20120006014A (ko) | 디아실에틸렌디아민 화합물 | |
WO2006020598A2 (en) | Amido compounds and their use as pharmaceuticals | |
PT2035379E (pt) | Inibidores da 11-beta-hidroxiesterëide desidrogenase 1 | |
EP0912513A1 (en) | Fibrinogen receptor antagonist prodrugs | |
KR20100065195A (ko) | 바이아릴 설폰아미드 유도체 | |
KR20200141026A (ko) | 비-융합된 티오펜 유도체 및 이의 용도 | |
ES2963111T3 (es) | Derivados de 4-(1,3,4-oxadiazol-2-il)piridina-2(1H)-ona como inhibidores de la histona desacetilasa 6 (HDAC6) para el tratamiento de infecciones E.G | |
WO2007069773A1 (en) | A pharmaceutical composition comprising an amide derivative | |
US20180250305A1 (en) | Nitric oxide-releasing prodrug molecule | |
CN106748922B (zh) | 一类新型砜酸衍生物、其制备方法及其作为药物的用途 | |
KR20060010717A (ko) | 신규한 아릴피페라지닐 화합물 | |
ES2782357T3 (es) | Inhibidores de IRE 1 alfa | |
JP2021514963A (ja) | ニューロトロフィンに関連する疾患を治療するためのトリアジン誘導体 | |
JP4422335B2 (ja) | グアニル酸シクラーゼ活性化剤としてのスルホニルアミノカルボン酸n−アリールアミド | |
EP3725780B1 (en) | Sulfonamide derivative or pharmaceutically acceptable acid-addition salt | |
JP4626353B2 (ja) | 置換又は無置換アミノ基を導入した4−ピリジルアルキルチオ基を有する新規環式化合物 | |
TR201808812T4 (tr) | Fenil derivesi. | |
KR20110045095A (ko) | Vegfr-2 수용체 및 단백질 티로신 키나아제 억제제인 피리딘 유도체 | |
WO2005030706A1 (ja) | アミド型カルボキサミド誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |